{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.2","upperLimit":"64.3","value":"49.8"},{"groupId":"OG001","lowerLimit":"24.4","upperLimit":"56.1","value":"39.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Response defined as no emetic or retching episodes and no rescue medication use during late onset phase (4-7 days post-chemotherapy) measured each cycle. Responses tabulated to 4 items of Morisky Medication Adherence measure for each treatment group by cycle of therapy. Elements summarized of Morrow Assessment of Nausea and Emesis and for pill counts/compliance for each treatment group by cycle of therapy. Descriptive statistics summarize total scores for Osoba Module, used to measure effect of nausea and vomiting on quality of life, for each treatment group by cycle of therapy. Osoba Nausea and Emesis Module; higher scores indicate worse quality of life. Morisky Medication Adherence Scale. Higher scores indicate higher compliance. Morisky Medication Adherence Scale is Yes=0 and No=1 , zero is the lowest level of medication adherence, and 4 is the highest level of medication adherence.","dispersionType":"95% Confidence Interval","groups":[{"description":"8 mg ondansetron given IV prior to Cycle 1 of Cisplatin then 34.3 mg granisetron patch applied and then reapplied every 7 days prior to Cycles 2-5 of Cisplatin.","id":"OG000","title":"Arm 1: Transdermal Granisetron"},{"description":"8 mg ondansetron given IV prior to Cycles 1-5 then 8 mg oral ondansetron every 8 hours for 72 hours following each Cisplatin and PRN in-between cycles.","id":"OG001","title":"Arm 2: Oral Ondansetron"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline, up to 7 days post-chemotherapy, through 5 cycles of chemotherapy measured each cycle, an average of 6 weeks","title":"Percentage of Participants With Response Rate to Anti-Emetic Therapy Days 4-7 Each Chemotherapy Cycle","type":"PRIMARY","unitOfMeasure":"percentage of participants"}